-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the increase of cardiovascular disease and the rapid development of biotechnology, interventional radiology, with its multiple advantages of minimally invasion, rapid, safe and effective, has made rapid progress in many clinical fields, especially in the fields of cardiovascular, cerebrovascular, exovascular and oncology, and the process of localization of interventional therapeutic devices in China is expected to accelerate in the future.
Cardiovascular interventional therapy is a new diagnosis and treatment technology, through the puncture of the surface blood vessels, in the continuous digital shadow reduction of the continuous cast into the heart catheter, the use of specific cardiac catheter operation technology for the diagnosis and treatment of patients. Compared with internal surgery, interventional therapy has the advantages of greatly increasing the concentration of drugs in lesions, small trauma, reducing the risk of anesthesia, and recovering quickly. At present, interventional therapy has become one of the three modern medical treatment methods which are side by side with traditional medical treatment and surgical treatment. At present, interventional radiology diagnosis and treatment technology is widely used in various professions, such as medical foundation and clinical, according to the operation method can be divided into vascular interventional therapy and non-vascular interventional therapy technology.
in recent years, cardiovascular intervention, especially for coronary artery disease intervention devices, has become a global focus on research and development, which is closely related to the high incidence and fatality of cardiovascular disease. Data show that about 20 million people die each year from cardiovascular disease, accounting for 20 to 30 percent of all deaths worldwide. The global market for interventional cardiovascular disease treatment is increasing year by year, exceeding US$20 billion in 2015.
the aging of the population and the high incidence of chronic diseases such as cardiovascular and cerebrovascular diseases, China's cardiovascular intervention device market will usher in rapid expansion opportunities, the future development prospects of the industry is broad. China Cardiovascular Disease Report statistics show that in 2015, China's cardiovascular disease patients have reached 290 million people, including 270 million people with hypertension, stroke patients more than 7 million people. In recent years, the number of cardiovascular diseases in China has maintained a rapid growth trend, and the fatality rate has been increasing. Due to the long cure cycle of cardiovascular disease, the social burden of patients is increasing, which has become a major public health problem.
the development of China's medical device industry is relatively lagging behind, especially in the large-scale high-end equipment, high-tech field in the pattern of foreign monopoly. Due to the high technical barriers of interventional therapy technology, only the more mature coronary support products have basically completed localization, and there is still a large room for import substitution of other products.
cardiovascular intervention device mainly includes stents, balloon dilation catheters and supporting guide wire, catheters, embolism and other components. The development of cardiovascular intervention devices represented by stents has now entered the fourth generation of research and development stage, and the domestic crown stent in the technology of continuous breakthrough, the proportion of localization has reached more than 80%, reflecting the growing maturity of domestic stent product technology. With the gradual landing of the series of support policies and the continuous innovation of domestic medical device product development, the overall import substitution process of domestic high-end medical devices is expected to accelerate. (Shanghai Securities News)